0000721371--06-302025Q1falsehttp://fasb.org/us-gaap/2024#GainLossOnSalesOfAssetsAndAssetImpairmentChargesxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesutr:Ratexbrli:purecah:statescah:numberOfUSTerritoriescah:lawsuitcah:plaintiffiso4217:JPYcah:segmentcah:Segmentscah:Reportable_Segments00007213712024-07-012024-09-3000007213712024-10-2500007213712023-07-012023-09-3000007213712024-09-3000007213712024-06-300000721371us-gaap:CommonStockMember2024-06-300000721371us-gaap:RetainedEarningsMember2024-06-300000721371us-gaap:TreasuryStockCommonMember2024-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000721371us-gaap:NoncontrollingInterestMember2024-06-300000721371us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000721371us-gaap:CommonStockMember2024-07-012024-09-300000721371us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000721371us-gaap:RetainedEarningsMember2024-07-012024-09-300000721371us-gaap:CommonStockMember2024-09-300000721371us-gaap:RetainedEarningsMember2024-09-300000721371us-gaap:TreasuryStockCommonMember2024-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000721371us-gaap:NoncontrollingInterestMember2024-09-300000721371us-gaap:CommonStockMember2023-06-300000721371us-gaap:RetainedEarningsMember2023-06-300000721371us-gaap:TreasuryStockCommonMember2023-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000721371us-gaap:NoncontrollingInterestMember2023-06-3000007213712023-06-300000721371us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000721371us-gaap:CommonStockMember2023-07-012023-09-300000721371us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000721371us-gaap:RetainedEarningsMember2023-07-012023-09-300000721371us-gaap:CommonStockMember2023-09-300000721371us-gaap:RetainedEarningsMember2023-09-300000721371us-gaap:TreasuryStockCommonMember2023-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000721371us-gaap:NoncontrollingInterestMember2023-09-3000007213712023-09-300000721371cah:OptumRxMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercah:PharmaceuticalAndSpecialtySolutionsMember2023-07-012024-06-300000721371cah:IntegratedOncologyNetworkMember2024-07-012024-09-300000721371cah:SpecialtyNetworksMember2023-07-012024-06-300000721371cah:TransactionDataSystemInvestmentMember2024-09-300000721371cah:OutcomesDivestitureMember2023-07-012024-06-300000721371cah:TransactionDataSystemInvestmentMember2023-07-100000721371us-gaap:EmployeeSeveranceMember2024-06-300000721371us-gaap:FacilityClosingMember2024-06-300000721371us-gaap:EmployeeSeveranceMember2024-07-012024-09-300000721371us-gaap:FacilityClosingMember2024-07-012024-09-300000721371us-gaap:EmployeeSeveranceMember2024-09-300000721371us-gaap:FacilityClosingMember2024-09-300000721371cah:PharmaceuticalAndSpecialtySolutionsMember2024-06-300000721371cah:GMPDMember2024-06-300000721371us-gaap:AllOtherSegmentsMember2024-06-300000721371cah:PharmaceuticalAndSpecialtySolutionsMember2024-07-012024-09-300000721371cah:GMPDMember2024-07-012024-09-300000721371us-gaap:AllOtherSegmentsMember2024-07-012024-09-300000721371cah:PharmaceuticalAndSpecialtySolutionsMember2024-09-300000721371cah:GMPDMember2024-09-300000721371us-gaap:AllOtherSegmentsMember2024-09-300000721371cah:GMPDMember2023-07-012023-09-300000721371cah:IPRDTrademarksandOtherMember2024-09-300000721371us-gaap:CustomerRelationshipsMember2024-09-300000721371cah:TrademarksAndPatentsMember2024-09-300000721371us-gaap:DevelopedTechnologyRightsMember2024-09-300000721371cah:IPRDTrademarksandOtherMember2024-06-300000721371us-gaap:CustomerRelationshipsMember2024-06-300000721371cah:TrademarksAndPatentsMember2024-06-300000721371us-gaap:DevelopedTechnologyRightsMember2024-06-300000721371us-gaap:CommercialPaperMember2024-09-300000721371us-gaap:RevolvingCreditFacilityMember2024-09-300000721371cah:CommittedReceivablesSalesFacilityProgramMembercah:ShortTermCreditFacilitiesMember2024-09-300000721371cah:ShortTermCreditFacilitiesMember2024-09-300000721371us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMember2024-10-082025-10-070000721371us-gaap:SubsequentEventMemberus-gaap:CommercialPaperMember2024-10-080000721371cah:CVSHealthMember2024-07-012024-09-300000721371cah:NewYorkOpioidStewardshipActMember2018-04-300000721371cah:TotalOpioidLitigationMember2024-09-300000721371cah:TotalOpioidLitigationMember2023-07-012024-06-300000721371cah:OpioidLawsuitsMember2024-09-300000721371cah:OpioidLawsuitsMember2024-07-012024-09-300000721371cah:OpioidLawsuitsMemberstpr:AL2023-07-012024-06-300000721371cah:OpioidLawsuitsMemberstpr:AL2023-11-300000721371cah:OpioidLawsuitsMembercah:CityOfBaltimoreMember2024-08-310000721371cah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2021-07-012024-10-310000721371cah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2024-11-012038-06-300000721371cah:OpioidLawsuitsMemberstpr:WV2022-07-310000721371cah:OpioidLawsuitsMembernaics:ZZ9211502022-10-310000721371cah:PrivatePartiesMembercah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2024-10-310000721371cah:PrivatePartiesMembercah:ClassActionLawsuitsMembercah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2024-10-310000721371cah:PrivatePartiesMembercah:ClassActionLawsuitsMembercah:OpioidLawsuitsMember2024-09-300000721371cah:PrivatePartiesMemberstpr:GAcah:OpioidLawsuitsMember2023-04-012023-06-300000721371cah:OpioidLawsuitsMember2023-07-012024-06-300000721371cah:IVCApril2023AgreementMembercah:ProductLiabilityLawsuitsMember2023-04-302023-04-300000721371cah:ProductLiabilityLawsuitsMembercah:IVCApril2023AgreementMember2023-04-300000721371cah:ProductLiabilityLawsuitsMembercah:IVCApril2023AgreementMember2023-05-012023-09-300000721371cah:ProductLiabilityLawsuitsMember2022-07-012023-06-300000721371cah:ProductLiabilityLawsuitsMembersrt:MinimumMember2024-09-300000721371cah:FY24Q1GoodwillImpairmentGMPDMember2023-07-012024-06-300000721371cah:FY24Q1GoodwillImpairmentGMPDMember2023-10-012024-06-300000721371srt:MinimumMember2024-09-300000721371srt:MaximumMember2024-09-300000721371srt:MinimumMemberus-gaap:InternalRevenueServiceIRSMember2024-07-012024-09-300000721371us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000721371us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000721371us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000721371us-gaap:FairValueInputsLevel12And3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000721371us-gaap:FairValueMeasurementsRecurringMember2024-09-300000721371us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000721371us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000721371us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000721371us-gaap:FairValueInputsLevel12And3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000721371us-gaap:FairValueMeasurementsRecurringMember2024-06-300000721371us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000721371us-gaap:CashFlowHedgingMember2024-07-012024-09-300000721371us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000721371us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000721371us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2024-10-012025-09-300000721371cah:September2025Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000721371cah:June2027Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000721371cah:September2025Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000721371us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercah:January2023Member2023-09-300000721371cah:January2023Member2023-07-012023-09-300000721371us-gaap:ForeignExchangeContractMember2024-07-012024-09-300000721371us-gaap:ForeignExchangeContractMember2023-07-012023-09-300000721371us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-07-012024-09-300000721371us-gaap:FairValueInputsLevel2Member2024-09-300000721371us-gaap:FairValueInputsLevel2Member2024-06-300000721371cah:A375MillionShareRepurchaseProgramMember2024-07-012024-09-300000721371cah:A375MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2024-07-012024-09-300000721371cah:A375MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2024-07-012024-09-300000721371cah:A375MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMemberus-gaap:SubsequentEventMember2024-07-012024-10-300000721371cah:A375MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMemberus-gaap:SubsequentEventMember2024-07-012024-10-300000721371cah:A500MillionShareRepurchaseProgramMember2023-07-012023-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-07-012023-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-07-012023-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-07-012023-10-310000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-10-312023-10-310000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2024-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-07-012024-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2024-07-012024-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-07-012024-09-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-09-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalAndSpecialtySolutionsMember2024-07-012024-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalAndSpecialtySolutionsMember2023-07-012023-09-300000721371us-gaap:OperatingSegmentsMembercah:GMPDMember2024-07-012024-09-300000721371us-gaap:OperatingSegmentsMembercah:GMPDMember2023-07-012023-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercah:NuclearAndPrecisionHealthSolutionsMember2024-07-012024-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercah:NuclearAndPrecisionHealthSolutionsMember2023-07-012023-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercah:AtHomeSolutionsMember2024-07-012024-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercah:AtHomeSolutionsMember2023-07-012023-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercah:OptiFreightMember2024-07-012024-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercah:OptiFreightMember2023-07-012023-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2024-07-012024-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2023-07-012023-09-300000721371us-gaap:OperatingSegmentsMember2024-07-012024-09-300000721371us-gaap:OperatingSegmentsMember2023-07-012023-09-300000721371us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000721371us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000721371country:US2024-07-012024-09-300000721371country:US2023-07-012023-09-300000721371us-gaap:NonUsMember2024-07-012024-09-300000721371us-gaap:NonUsMember2023-07-012023-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalAndSpecialtySolutionsMember2024-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalAndSpecialtySolutionsMember2024-06-300000721371us-gaap:OperatingSegmentsMembercah:GMPDMember2024-09-300000721371us-gaap:OperatingSegmentsMembercah:GMPDMember2024-06-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2024-09-300000721371us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2024-06-300000721371us-gaap:CorporateNonSegmentMember2024-09-300000721371us-gaap:CorporateNonSegmentMember2024-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000721371us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000721371us-gaap:PerformanceSharesMember2024-07-012024-09-300000721371us-gaap:PerformanceSharesMember2023-07-012023-09-300000721371us-gaap:RestrictedStockUnitsRSUMember2024-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2024-09-300000721371us-gaap:PerformanceSharesMembersrt:MinimumMember2023-07-012023-09-300000721371us-gaap:PerformanceSharesMembersrt:MinimumMember2024-07-012024-09-300000721371us-gaap:PerformanceSharesMembersrt:MaximumMember2023-07-012023-09-300000721371us-gaap:PerformanceSharesMembersrt:MaximumMember2024-07-012024-09-300000721371us-gaap:PerformanceSharesMember2024-06-300000721371us-gaap:PerformanceSharesMember2024-09-30
美國
證券交易委員會
華盛頓特區20549
10-Q
根據1934年證券交易法第13或15(d)節的季度報告
在截至的季度期間 2024 年 9 月 30 日
或者
根據1934年證券交易法第13或15(d)節的轉型報告書
過渡期從________到_________
委員會備案號碼:1-11373
卡地納健康公司
(根據其章程規定的註冊人準確名稱)
俄亥俄州31-0958666
(國家或其他管轄區的
公司成立或組織)
(美國國內國稅局僱主
唯一識別號碼)
卡地納健康總部地址:7000 Cardinal Place,都柏林,俄亥俄州43017
,(主要行政辦公地址)(郵政編碼)
(614757-5000
(註冊人電話號碼,包括區號)
在法案第12(b)條的規定下注冊的證券:
每一類的名稱交易標誌在其上註冊的交易所的名稱
普通股 (無面值)卡地納健康請使用moomoo賬號登錄查看New York Stock Exchange
用勾號標識: (1) 在過去的12個月內,提交了《證券交易法》第13條或第15(d)條所要求提交的所有報告。(或對於註冊者要求提交這些報告的更短期間)(2) 在過去的90天內一直遵守報告要求。        否  
請通過複選標記指示,報告人是否已根據《規則405》和《S-t條例規定》(本章第232.405條)的規定,在過去12個月內(或被要求提交此類文件的較短期間內)已電子提交每一個交互式數據文件。      否  
請用複選標記指示報名者是否爲大型加速量文件者、加速量文件者、非加速量文件者、較小報告公司或新興增長公司。請查看交易所法案規則120億2中對「大型加速量文件者」、「加速量文件者」、「較小報告公司」和「新興增長公司」的定義。
大型加速報告人加速文件提交人
非加速文件提交人更小的報告公司
新興增長公司
如果是新興成長型公司,請勾選,以表示註冊公司已選擇不使用根據《交易法》第13(a)節規定提供的任何新的或修訂的財務會計準則的延長過渡期。
請選擇複選標記,表明報名者是外殼公司(如《交易所法》第120億.2條所定義)。 是  沒有。 
截至2024年10月25日,註冊股東的普通股數量,無面值,如下: 242,010,503.



卡地納健康
2025財年第一季度10-Q表格
目錄
卡地納健康簡介
成立於1979年的俄亥俄州公司Cardinal Health, Inc.是一家全球醫療保健服務和產品公司,爲醫院、醫療系統、藥房、日間手術中心、臨床實驗室、醫生辦公室和居家患者提供定製解決方案。我們提供醫藥和醫療產品,以及增強供應鏈效率的經濟實惠解決方案。我們連接患者、醫護人員、付款方、藥劑師和製造商,實現綜合的護理協調。
我們將財務結果報告分爲兩個可報告部門:藥品與特殊解決方案(「藥品」)部門和全球醫療產品與分銷(「GMPD」)部門。 所有未達到要求的重要性而無需單獨報告的運營部門納入其他板塊,包括核醫學和精準健康解決方案,家庭解決方案和OptiFreight。® 物流。 在本報告中,「我們」,「我們的」,「我們的」和類似的代詞指的是君耐德健康公司及其絕大部分擁有的和合並的子公司,除非上下文另有要求。 我們的財政年度截至6月30日。 提及2025財政年度和2024財政年度以及FY25和FY24均指2025年6月30日結束或結束的財政年度,分別爲2024年6月30日。
前瞻性聲明
截至2024年9月30日的本季度10-Q表格(本" 10-Q 表格)(包括通過引用的信息)包括解釋期望、前景、估計和其他依賴未來事件或發展的"前瞻性聲明"。許多前瞻性聲明出現在管理層對財務狀況和經營業績的討論與分析("MD&A")中,但這份10-Q表格中還有其他前瞻性聲明,可以通過"期望"、"預期"、"打算"、"計劃"、"相信"、"將"、"應該"、"可能"、"可能"、"可能"、"項目"、"繼續"、"可能" 等類似表達詞語進行識別,包括反映未來結果或指導、展望性聲明、及費用預收的聲明。這些問題受到可能導致實際結果與所做、預測或暗示結果大相徑庭的風險和不確定性的影響。其中最重要的風險和不確定性在本10-Q表格及附件 99.1 中有描述,並在截至2024年6月30日的我們的年度報告10-K("2024第10-K表")的"風險因素"中有提及。本10-Q表格中的前瞻性聲明僅截至本文件的日期。除非適用法律要求,否則我們不承擔更新或修訂任何前瞻性聲明的義務。
非依照普遍公認會計准則的財務措施
在MD&A的「綜合業績概覽」部分,我們使用基於我們的合併財務數據而產生的財務指標,但這些指標並未在按照美國通用會計準則(「GAAP」)編制的簡明合併財務報表中呈現。這些措施被認爲是證券交易委員會(「SEC」)規則下的「非GAAP財務措施」。我們使用這些非GAAP財務措施的原因以及與其最直接可比的GAAP財務措施的調和包括在本10-Q表格中MD&A後面「非GAAP財務措施的解釋和調和」部分。

 1
卡地納健康 | Q1 2025財年10-Q表格


MD&A概述
管理層對財務狀況和經營結果的討論和分析
以下討論和分析關注財務狀況和經營結果中的重大變化,包括在2024年9月30日和2024年6月30日的簡明合併資產負債表以及2024年9月30日和2023年的三個月的簡明合併損益表和現金流量表中來自經營活動和外部來源的現金流量的數量和確定性。所有比較均針對上一年度的時期進行,除非另有說明。我們此前報告的部門業績已被重新調整以符合我們的新報告結構,並反映由報告結構變更驅動的取消內部板塊營收和分配的公司科技和共享功能費用的變化。所有修訂均體現在本表格10-Q中。詳見 注1 《簡明合併財務報表附註》的附加信息。本討論和分析應與2024年10-k中包含的MD&A一併閱讀。

 2
卡地納健康 | Q1 2025財年10-Q表格


MD&A概述
合併業績概況
營業收入
2024年9月30日結束的三個月的營業收入由於OptumRx合同到期而下降了4%,部分被現有客戶品牌和專業藥品銷售增長部分抵消。

根據美國通用會計原則和非美國通用會計原則的營運盈虧
截至9月30日的三個月
(單位百萬)20242023變更
根據公認會計原則,運營收益/(虧損)
$568 $(32)N.M.
重組和員工分流24 25 
攤銷及其他併購相關成本74 64 
資產處置的淨損益和資產減值(1)541 
訴訟(收入)/費用,淨額(40)(41)
非GAAP經營利潤$625 $557 12 %
元件總和和某些計算結果可能反映四捨五入調整。
2024年9月30日結束的三個月內,我們的GAAP營業收入爲56800萬美元,而2023年9月30日結束的三個月內,我們的GAAP營業虧損爲3200萬美元,其中包括與GMPD部分相關的稅前商譽減值損失影響爲58500萬美元。
非根據美國通用會計準則計算的營運收益增長了12%,從去年同期的62500萬美元增加,主要是由於品牌藥品和特殊藥品產品的貢獻增加,其中包括新冠疫苗分發季節提前對銷售額的積極影響,以及我們的仿製藥項目表現。


卡地納健康 | Q1 2025財年10-Q表格
3



MD&A概述
根據通用會計準則和非通用會計準則攤薄後每股收益
截至9月30日的三個月
(每股美元)
2024 (2)
2023 (2),(3)
改變
GAAP 攤薄後每股 (1)
$1.70 $(0.05)N.M。
重組和員工遣散費0.07 0.07 
攤銷和其他與收購相關的成本0.22 0.19 
資產處置減值和(收益)/虧損,淨額 (4)
 1.63 
訴訟(追回)/費用,淨額(0.11)(0.12)
非公認會計准則攤薄後每股收益 (1)
$1.88 $1.72 9 %
元件總和和某些計算結果可能反映四捨五入調整。
(1) 每股收益攤薄後歸屬於Cardinal Health, Inc.的股份。
(2) 調節項目在本表中均已扣除稅項。請參閱《GAAP與非GAAP財務調和表中每個調節項目的稅效量的量化》,詳細說明和非GAAP財務指標調和。
(3) 截至2023年9月30日三個月,根據共24900萬普通股的加權平均數計算GAAP攤薄後每股收益以及從GAAP到非GAAP每股調整項目的EPS影響,由於我們在該期間的GAAP淨虧損導致其反攤薄效應,此計算排除了可能具有稀釋性的證券。截至2023年9月30日三個月,非GAAP攤薄後每股收益根據25000萬普通股的加權平均數計算,其中包括可能具有稀釋性的股份。
(4) 截至2023年9月30日三個月的資產減值和資產處置損益淨額包括一個稅前的優良意向減值費用爲58500萬美元,與GMPD業務部門相關。 對於2024財年,與此費用相關的淨稅收益爲4500萬美元,並已計入年度有效稅率中。 因此,截至2023年9月30日三個月的稅收收益大約增加了10200萬美元,並增加了截至2024財年餘下時間的所得稅提備。
2024年9月30日結束的三個月內,由於上文中影響着GAAP經營收益/(損失)的因素,GAAP攤薄後每股收益增加。與2023年9月30日結束的三個月相比,GMPD部門的商譽減值費對GAAP攤薄後每股收益造成了每股(1.76)美元的稅後影響。
非GAAP攤薄後每股收益增長9%,從上一年同期的$1.88增加,主要是由於上述影響非GAAP營運收益的因素。

現金和等價物
截至2024年9月30日,我們的現金及現金等價物餘額爲29億美元,而在2024年6月30日則爲51億美元。2024年9月30日結束的三個月內,經營活動中淨現金流出16億美元,主要受OptumRx合同涉及的負淨營運資本減少以及向供應商付款時間的影響。該季度的經營活動現金流也包括我們根據"全國阿片類藥物訴訟和解協議"支付的3.66億美元年度款項的影響。此外,我們用於股份回購的現金金額爲37500萬美元,用於資本支出的現金金額爲9000萬美元。



 4
卡地納健康 | Q1 2025財年10-Q表格


MD&A概述
2025財政重大發展及趨勢
藥品和特殊解決方案部門
OptumRx合同
2024年4月22日,我們宣佈與OptumRx的藥品分銷合同將於2024年6月底到期。 2024財年,向OptumRx的銷售額佔我們營業收入的17%; 但是,由於交易種類的原因,向OptumRx的銷售額的營業利潤率明顯低於整體制藥業務部門的水平。 OptumRx合同的到期以及與這些合同相關的負淨運營資本的解除不利地影響了我們截至2024年9月30日的三個月的經營業績,包括分部利潤、財務狀況和現金流。 儘管我們預計通過吸引新客戶、現有客戶的增長和成本節省來抵消影響,但我們預計在2025財年的其餘時間內仍會持續受到一些不利影響。
收購
2024年9月20日,我們宣佈達成協議,以現金11億美元的價格收購Integrated Oncology Network(「ION」),ION是一家由醫生領導的獨立社區腫瘤醫療網絡,擁有50多個執業場所分佈在10個州,有100多名醫生。ION在其會員網站提供醫療腫瘤學、放射腫瘤學、泌尿外科診斷檢測和其他輔助服務的完整醫療連續體。此次收購將進一步發展我們的Navista腫瘤醫療實踐聯盟,並且預期擴大我們的全面臨床和實踐管理解決方案套件,旨在支持獨立社區腫瘤醫療實踐。該交易需滿足慣例的結束條件,包括獲得必要的監管批准。我們計劃用可用現金和現有的借款安排資助此次收購。
2024年3月18日,我們以12億美元的現金價格完成了對Specialty Networks的收購。此次收購進一步擴大了我們在關鍵治療領域的產品範圍,並加快了我們與生物製藥製造商在上游數據和研究機會方面的合作。
品牌藥品
在2024財政年度,我們看到GLP-1類藥物需求增加,儘管出現週期性供應短缺,但我們的銷售額顯著增長。這些增加的銷售額對我們的製藥部門和2024財政年度的整體營業收入產生了積極影響;然而,GLP-1銷售並未對部門利潤產生實質性貢獻。未來對這些藥物的需求是不可預測的,我們滿足需求的能力可能會受到額外供應限制的影響。
在2024財政年度,我們開始分發商業化生物-疫苗,這是在美國食品藥品監督管理局(FDA)批准後進行的。這些疫苗的分發給我們的製藥業務利潤在2024財政年度帶來了比預期更大的好處,尤其是在第二季度。我們預計COVID-19疫苗的分發將繼續對我們的製藥業務利潤在2025財政年度產生有利影響,但影響程度將低於2024財政年度。 2024年8月,FDA批准了2024-2025年度商業化COVID-19疫苗,我們的製藥業務利潤在2025財政年度第一季度受到這些疫苗的分發的積極影響。由於COVID-19疫苗分發的季節性提前推出,相較於去年同期,我們預計2025財政年度第二季度來自疫苗分發的貢獻將較低。
通用程序
我們的藥品部門仿製藥項目的表現對截至2024年9月30日的三個月的藥品部門利潤同比比較產生了積極影響。藥品部門仿製藥項目包括了仿製藥產品推出的影響、客戶規模、定價變化、西維斯健康公司("西維斯健康")合作的Red Oak Sourcing,以及仿製藥合同製造和採購成本等內容。
通用藥品客戶銷售量、價格變動、客戶合同續簽、通用藥品製造商定價變化以及通用藥品合同製造和採購成本的頻率、時間、規模和利潤影響都會影響藥品業務板塊的利潤,並且受到風險和不確定性的影響。這些風險和不確定性可能會影響藥品業務板塊的利潤以及2025財年及以後的綜合運營收益。


卡地納健康 | Q1 2025財年10-Q表格
5



MD&A概述
全球貨幣醫療產品和分銷部門
成交量
我們在2024財年經歷了卡地納健康品牌醫療產品銷售增長,並預計在2025財年及以後會進一步增長。這種預期銷售增長的時機、規模和利潤影響受風險和不確定性影響,可能會影響GMPD部門的利潤。

 6
卡地納健康 | Q1 2025財年10-Q表格


MD&A經營結果
經營結果
營業收入
36374947802332370
截至9月30日的三個月
(單位:百萬)20242023改變
製藥和專業解決方案$47,990 $50,588 (5)%
全球醫療產品和分銷3,123 3,032 3 %
其他1,186 1,051 13 %
分部總收入52,299 54,671 (4)%
企業(22)(21)N.M。
總收入$52,277 $54,650 (4)%

藥品和專業解決方案
藥品部門的營業收入由於OptumRx合同到期,部分抵消了現有客戶品牌和特殊藥品銷售增長,從去年同期下降了5%,至480億美元。
全球貨幣醫療產品和分銷
GMPD部門的營業收入增長了3%。 31億美元,主要是由於現有客戶的交易量增加。
其他
其他收入增加了13%,達到12億美元 由於在家庭解決方案、核能與精密健康解決方案以及OptiFreight領域的增長,與去年同期相比增長® 物流運營部門。

產品銷售成本
由於影響營業收入和毛利率變化的因素,產品銷售成本下降了5%至504億美元,較上年同期。







卡地納健康 | Q1 2025財年10-Q表格
7



MD&A經營結果
毛利率
892893
截至9月30日的三個月
(單位百萬)20242023變更
毛利率$1,902 $1,743 9 %
毛利率由去年同期增加9%,主要是由於品牌藥品和特殊藥品產品的貢獻增加,以及製藥板塊中我們的仿製藥項目表現良好所致。
毛利率增長45個點子,從上年同期的3.64%增至主要是由於品牌藥品和特殊藥品產品的貢獻增加,以及製藥部門產品組合的有利變化,主要是由於OptumRx合同到期的推動。

銷售、一般及行政費用("SG&A")
截至9月30日的三個月
(單位:百萬)20242023改變
銷售和收購費用$1,277 $1,186 8 %
銷售及一般行政開支增加了8%,至13億美元,主要是由於更高的健康福利成本和爲現有客戶支持增長銷售所產生的成本。




 8
卡地納健康 | Q1 2025財年10-Q表格


MD&A經營結果
分段利潤
我們評估部門績效的基礎是部門利潤,以及其他指標。請參見 附註13 有關部門利潤的更多信息,請參閱"基本報表附註"。

截至9月30日的三個月
(單位百萬)20242023變更
醫療藥品和特色解決方案$530 $456 16 %
全球貨幣醫療產品和分銷8 12 N.M.
其他104 96 8 %
總業務利潤642 564 14 %
公司(74)(596)N.M.
總合並營運利潤/(損失)
$568 $(32)N.M.
醫療藥品和特色解決方案
藥品部門利潤增長了16%,從去年同期的53000萬美元增加到主要歸功於品牌藥品和特殊藥品產品的貢獻增加,其中包括COVID-19生物-疫苗分發季節提前對銷售的有利影響,以及我們的仿製藥計劃的表現。部分抵消了OptumRx合同的到期。
全球貨幣醫療產品和分銷
由於較高的製造業和衛生福利成本,GMPD部門利潤從去年同期的800萬美元下降,但主要被淨通貨膨脹影響改善、包括緩解行動的效果以及來自現有客戶增長部分抵消。
其他
其餘利潤由於OptiFreight的表現,同比增長8%,達到10400萬美元。® 物流。
公司
2024年9月30日結束的三個月內公司發生的變化,是由接下來討論的"綜合經營收益/(虧損)的其他要素"部分中討論的因素引起的。


卡地納健康 | Q1 2025財年10-Q表格
9



MD&A經營結果
合併經營利潤/(損失)的其他元件
除營業收入、毛利率和SG&A費用之外,已討論的,合併運營收益/(虧損)受到以下因素的影響:
截至9月30日的三個月
(單位百萬)20242023
重組和員工分流$24 $25 
攤銷及其他併購相關成本74 64 
資產處置的淨損益和資產減值(1)541 
訴訟(收入)/費用,淨額(40)(41)
重組和員工遣散
截至2024年9月30日的三個月內,重組和員工裁員成本主要與實施某些全企業節約成本措施及某些旨在合理化我們的製造業務的計劃相關。截至2023年9月30日的三個月內,重組和員工裁員成本主要與我們策略、組合、資本配置框架和運營審查相關的某些項目以及實施某些全企業節約成本措施相關聯。
攤銷及其他併購相關成本
截至2024年9月30日止三個月的收購相關無形資產攤銷額分別爲6,800萬美元和6,400萬美元,而2023年同期分別爲6,400萬美元。
資產減值及資產處置(收益)/損失,淨額
在2023年9月30日結束的三個月內,我們承認了一項5.85 億美元的稅前非現金商譽減值費用,與 GMPD 部門有關,並承認了一項總額爲 5300萬美元的稅前收益,與出售 Outcomes™ 業務有關。
訴訟(收回)/費用,淨額
在2024年和2023年截至9月30日的三個月內,我們承認作爲集體成員或原告在集體訴訟反壟斷訴訟中收到的淨收入分別爲4300萬和4100萬美元。.
稅前收益
除上述討論的項目外,稅前收入還受以下影響:
截至9月30日的三個月
(單位百萬)20242023變更
其他收入/費用,淨額$(5)$N.M.
利息費用,淨額32 11 N.M.

利息支出,淨額
淨利息費用增至3,200萬美元,主要是由於現金及等價物以及金融工具利息收入減少。



 10
卡地納健康 | Q1 2025財年10-Q表格


MD&A經營結果
所得稅準備/(受益於)
2024年9月30日結束的三個月內,有效稅率分別爲23.0%和75.1%。2024年9月30日結束的三個月的有效稅率下降,與去年同期相比,主要是由於去年商譽減值費用的稅務影響。詳見《基本報表附註》。 注8 有關更多信息,請參閱「基本報表附註」
商譽減值損失的稅務影響
2023年9月30日結束的三個月內,我們確認了一項5.85億美元的稅前減值準備,涉及GMPD部門。與此項準備相關的淨稅收益爲2024財年的4500萬美元。
除非某項貨物因爲飛凡或罕見而被視爲離散項目,否則該項目的稅收影響將包含在我們估計的年度有效稅率中。當項目通過我們估計的年度有效稅率識別時,我們將該估計年度有效稅率應用於本年度累計前所得稅額,以計算本季度和本年度至今的所得稅影響。離散項目的稅收影響將在發生的那一期間內全部確認。
2023年9月30日結束的三個月內,商譽減值損失的稅收影響被納入了我們估計的年度有效稅率中,因爲這是不被視爲飛凡或不經常的,並且考慮到我們在以前的財政年度記錄了商譽減值。不可抵扣商譽的影響提高了2024財年的估計年度有效稅率。將較高稅率應用於2023年9月30日結束的三個月的稅前虧損,導致確認約1.02億美元的額外臨時稅收益,影響了2023年9月30日結束的三個月以及資產負債表中的預付費用和其他資產中的應收所得稅費用/(收益)在2023年9月30日的簡明合併收支表中。這一臨時稅收益在2024財年的其餘季度中逆轉。
支柱二舉措的稅務影響
2021年12月,經濟合作與發展組織("OECD")發佈了關於設立全球最低稅率爲15%的支柱二計劃的指導方針。這些規則通常於2025財年生效。我們正在密切關注發展,但目前我們並不預計這些規則會對我們的有效稅率產生實質影響。


卡地納健康 | Q1 2025財年10-Q表格
11



MD&A流動性和資本資源
流動性和資本資源
我們目前相信,基於可用的資本資源和預期的營運現金流,我們有足夠的資本資源來支持我們的運營和未來預期的現金需求,如下所述。如果我們決定進行一項或多項收購,取決於此類交易的規模和時間,我們可能需要通過資本市場融資。
現金和等價物
截至2024年9月30日,我們的現金及現金等價物餘額爲29億美元,與2024年6月30日的51億美元相比。截至2024年9月30日止三個月,運營活動產生的淨現金流出金額爲16億美元,這主要受到與OptumRx合同相關的淨營運資本逆轉以及向供應商支付的正常時間的影響。本季度運營活動中使用的現金還包括我們根據全國鴉片類藥物和解協議支付的3.66億美元年度款項的影響。此外,我們用於股份回購的現金爲37500萬美元,用於資本支出的現金爲9千萬美元。
截至2024年9月30日,我們的現金及現金等價物存放在主要銀行的現金存款帳戶中,或投資於高質量、短期流動性投資。
影響經營現金流量的營運資本變動可能會因客戶付款時間、存貨購買、向供應商付款和稅款支付等因素而出現顯著波動,以及由客戶和產品組合驅動的波動的營運資本需求。
2024年9月30日的現金及等價物餘額中包括境外子公司持有的47100萬美元現金。
其他融資安排和金融工具
信用額度和商業票據
2024年9月30日的現金和等價物以及營運現金流量之外,其他流動性來源包括20億美元的商業票據計劃,由200億美元的循環信貸設施支持,到2028年2月到期。 我們還通過2025年9月提供10億美元的承諾應收賬款銷售設施。 在2024年9月30日,我們的商業票據計劃,循環信貸設施或承諾的應收賬款銷售設施均沒有未償金額。
2024年10月,我們簽訂了一項新的364天循環信貸設施,根據該協議,我們將通過2025年10月獲得10億美元的承諾性流動性。 我們還將我們的商業票據計劃從20億美元增加到30億美元。
我們的循環信貸和承諾的應收賬款銷售設施要求我們維持不超過3.75比1的合併淨槓桿比率。截至2024年9月30日,我們符合這一財務約定。
長期債務
在2024年9月30日和2024年6月30日,我們的總長期債務,包括當前部分和其他短期借款,分別爲52億美元和51億美元。我們計劃在2024年11月到期時用來自2024財年債券發行的4千萬美元收入償還我們未償還的3.5%票據,其中2千萬美元被投資於短期定期存款,被分類爲預付費用和其他在我們的簡明合併資產負債表中。







 12
卡地納健康 | Q1 2025財年10-Q表格


MD&A流動性和資本資源
資本配置
阿片訴訟和解
截至2024年9月30日,我們擁有50億美元的資金用於與特定阿片訴訟相關的資金,詳細描述如下 注7 我們預計剩餘支付金額的大部分將在2038年之前發生。在2024年9月30日結束的三個月內,根據全國阿片和解協議,我們進行了第四次年度支付,金額爲3.66億美元。未來年度支付金額可能不同於我們已經支付的金額。
資本支出
截至2024年9月30日和2023年,資本支出分別爲9000萬美元和9200萬美元。
股息
董事會在2024年5月7日和8月15日分別批准了每股0.5056美元的季度股息,在年化基礎上爲每股2.02美元,分別於2024年7月15日和10月15日支付給於2024年7月1日和10月1日股權登記日持有的股東。

股份回購
2024年9月30日結束時的三個月內,我們在加速股份回購("ASR")計劃下投入了37500萬美元用於回購普通股。我們用可用現金進行回購。該計劃於2025財年第二季度結束,將現有股份回購授權剩餘金額減少至約31億美元。詳見基本報表註釋 注11 「基本財務報表附註」部分獲取更多信息。
綜合腫瘤學網絡收購
2024年9月20日,我們宣佈已簽署一項完全協議,收購由醫生領導的獨立社區腫瘤學網絡Integrated Oncology Network,收購價格爲11億美元現金,視情況進行調整。收購需滿足一般的結案條件,包括獲得所需的監管批准。


卡地納健康 | Q1 2025財年10-Q表格
13



MD&A其他項目

其他項目
2024年10-K表格中的MD&A部分涵蓋了我們在2024年6月30日結束的財政年度截至日的合同義務和現金需求。除了在我們擬議的收購綜合腫瘤網絡事項中提及的考慮以外,對那些項目沒有發生超出業務日常範圍之外的重大變更。
重要會計政策和敏感會計估計
以下討論和分析是對我們2024年度10-k表中列明的關鍵會計政策和敏感會計估計的補充披露。 2024年6月30日應當結合2024年度10-k表中包含的關鍵會計政策和敏感會計估計閱讀本討論和分析。
關鍵會計政策是指那些(i)對我們的財務狀況和經營業績可能產生重大影響,(ii)需要基於過去經驗和管理層判斷做出複雜和主觀估計的會計政策。其他人對同一事實和情況進行合理判斷可能形成不同的估計。由於估計本質上是不確定的,實際結果可能有所不同,包括由於"風險因素"中討論的風險和2024年10-k表格以及我們向SEC提交的其他文件中討論的其他風險。 2024年6月30日.
商譽
購買的商譽每年或存在減值因素時進行減值測試。商譽減值測試涉及估計報告單位的公允價值與各自賬面價值的比較,可以利用定性或定量評估進行。首先評估定性因素以判斷報告單位的公允價值是否很可能低於其賬面價值。如果判斷公允價值很可能不超過賬面價值,則進行定量測試。定量商譽減值測試涉及比較報告單位的估計公允價值與各自賬面價值。報告單位被定義爲經營部門或經營部門以下的一個層次(也稱爲組成部分)。
商譽減值測試涉及判斷,包括確定報告單位、定性評估事件和情況以判斷減值是否很可能存在,以及必要時估計適用報告單位的公允價值。我們的定性評估考慮了所有已確定事件和情況以及公允價值最相關的正面和負面影響因素的證據力和重要性,以判斷報告單位的公允價值是否很可能低於其賬面價值。
事件和情況的定性評估對判斷報告單位的公允價值是否很可能低於其賬面價值至關重要,還包括確定報告單位、定量測試是最關鍵的因素之一。我們的定性評估考慮了所有已確定事件和情況以及公允價值最相關的正面和負面影響因素的證據力和重要性,來判斷報告單位的公允價值是否很可能低於其賬面價值。
At-Home Solutions商譽
在我們2024財年年度減值測試中,At-Home Solutions報告單位的公允價值超過其賬面價值不到1%。未來現金流減少、貼現率增加或終值增長率下降等因素可能導致At-Home Solutions的商譽減值。截至2024年9月30日的三個月內,At-Home Solutions報告單位沒有出現商譽減值的跡象。
全球醫療產品和分銷商業
在2024財年期間,我們記錄了67500萬美元的與我們的GMPD報告單元相關的商譽減值損失。 GMPD商譽在2024財年第三季度完全減值。



卡地納健康 | Q1 2025財年10-Q表格
14



非依照美國通用會計準則衡量的財務指標的解釋和調和
非依照美國通用會計準則衡量的財務指標的解釋和調和
在這份10-Q表格的MD&A部分中,「綜合結果概況」章節包含了未按照通用會計準則計算的財務指標。
除了根據GAAP準則編制的財務信息對我們的業務進行分析外,我們還內部使用這些非GAAP財務指標來評估我們的業績,進行財務和運營規劃,並確定激勵報酬,因爲我們認爲這些指標爲我們的基礎業務表現提供了額外的視角,在某些情況下更與我們的業務績效密切相關。我們向投資者提供這些非GAAP財務指標作爲補充指標,以幫助讀者評估一年比一年的財務和運營結果受項目和事件的影響,並比較我們的表現與競爭對手的表現。然而,我們使用的非GAAP財務指標可能按不同方式計算,因此可能無法與其他公司使用的同類指標進行比較。我們披露的非GAAP財務指標不應被視爲對GAAP計算的財務指標的替代,或者優於財務指標,應仔細評估按照GAAP計算的財務結果和與這些基本財務報表相關的調節。
非GAAP財務指標的排除反映調整的基礎如下:
管理層認爲有必要從本報告中所呈現的非GAAP指標中排除以下項目,以便爲其自身和投資者評估業務的原因如下:
LIFO費用和信用額度 被排除,因爲驅動後進先出("LIFO")庫存費用或信用額度的因素,例如藥品製造商的價格上漲或通貨索等和年底存貨水平(該水平可能受到在我們財政年末之前顧客購買行爲的顯著影響)主要超出我們的控制,無法精確預測。從非GAAP指標中排除LIFO費用和信用額度有助於我們將當前財務結果與我們的歷史財務結果以及我們的同行公司的財務結果進行比較。在所述時期內我們沒有承認任何LIFO費用或信用額度。
與先前財政年度有關的州阿片評估 州阿片藥物的州評估部分是指在發生費用的期間之前銷售或分發的州評估。這部分被排除在非通用會計原則財務指標之外,因爲它是追溯應用於先前財政年度銷售的,包括它會掩蓋我們基礎業務的當前財政年度結果的分析。此外,雖然各州的法律可能要求我們持續支付,但與先前期間銷售有關的評估部分被認爲是一次性、非經常性項目。與先前財政年度有關的州阿片評估所得收入代表了因估計變更或基礎評估被法庭無效或製造商退款而導致的應計沖銷。
股東合作協議費用 包括法律、諮詢和其他與達成的協議(「合作協議」)有關的費用,卡地納健康、艾麗特聯合投資基金和艾麗特國際聯合投資基金(統稱「艾麗特」)。其中包括用於談判和完成合作協議的費用,以及董事會業務審查委員會根據此合作協議成立的費用,該委員會負責進行對我們的策略、組合、資本分配框架和業務的全面審查。我們已從非普遍公認會計准則指標中排除了這些費用,因爲這些費用不屬於或反映我們日常業務運營中的常規情況,可能會混淆對趨勢和財務表現的分析。
重組和員工離職成本 不包括在我們基礎業務的持續經營範圍內,包括但不限於與剝離業務、關閉和 consoli製造業-半導體設施、改變製造或分發產品方式、將產品製造轉移至其他位置、生產或業務流程外包/optning、員工離職和重新調整業務等相關的成本。
攤銷及其他併購相關成本其中包括交易成本、整合成本以及與有條件的對價義務公允價值變動有關的費用,這些費用被排除在外,因爲它們不屬於我們基礎業務的經營範圍,並且可以方便地比較我們當前財務業績與歷史財務業績以及我們同行公司的財務業績。此外,用於攤銷併購相關無形資產的費用是非現金金額,其金額和頻率變化較大,而且受收購的時間和規模影響較大,因此將其排除可以方便地比較歷史、當前和預測財務業績。我們還排除其他併購相關費用,這些費用與某項收購直接相關,但不符合確認在收購實體初始階段的標準。

卡地納健康 | Q1 2025財年10-Q表格
15



非依照美國通用會計準則衡量的財務指標的解釋和調和
作爲購買價格分配的一部分的資產負債表。這些成本也受到收購時間、複雜性和規模的顯著影響。
資產減值損失和資產處置損益除外,淨額是因爲這些項目並不發生在或反映我們正常業務操作中,且在時間和金額上本質上是難以預測的,在資產減值的情況下,這些是非現金金額,因此它們的排除有助於比較歷史、當前和預測的財務結果。
訴訟收入或費用淨額 被排除在外,因爲它們經常涉及可能發生在以前或多個期間的事件,並不在我們業務的正常過程中發生或反映,並且在時間和金額上本質上是不可預測的。
償還債務應付金額損失 由於這類費用通常不在正常業務過程中發生,可能會模糊趨勢和財務表現分析。此外,這類費用的金額和頻率並不一致,並且受債務清償交易的時間和規模的顯着影響。

•上面列出的每個項目的稅收影響是使用適用於該項目及其記錄區域的稅率和其他稅收屬性確定的。每項的毛收益,稅費和淨影響都在我們的GAAP到非GAAP協調中呈現。
定義
增長率計算:報告中的增長率是通過當前期結果與前期結果之差除以前期結果來確定的。
非通用會計淨營業收益: 淨營業收益/(虧損)不包括(1) LIFO費用/(信貸),(2)與先前財政年度有關的州阿片類藥物評估,(3)股東合作協議費用,(4)重組和員工遣散補償,(5)攤銷和其他與收購相關的成本,(6)資產減值和處置的(收益)/損失,以及(7)訴訟(收入)/費用,淨額。
非通用會計標準稅前盈利: 稅前盈利/(虧損)不包括(1)先進先出法(LIFO)費用/(借項),(2)與之前財政年度有關的州阿片類藥物評估費用,(3)股東合作協議成本,(4)重組和員工裁員費用,(5)攤銷及其他併購相關費用,(6)資產減值和資產處置收益/(損失),(7)訴訟(收入)/費用淨額和(8)提前償還債務損失。
歸屬於Cardinal Health, Inc. 的非公認會計准則淨收益: 一個t 收益/(虧損) 歸屬於Cardinal Health, Inc.,不包括 (1) LIFO費用/(貸項),(2)與前一財政年度相關的州阿片類藥物評估,(3)股東合作協議成本,(4)重組和員工遣散費,(5)攤銷和其他收購相關成本,(6)資產處置減值和(收益)/虧損,淨額,(7)訴訟(追回)/費用,淨額和(8))提前清償債務造成的損失。
非通用會計淨稅率: 所得稅貸款準備金/(受益自)調整爲(1)LIFO費用/(借項),(2)與前一財政年度相關的州阿片三檢評估,(3)股東合作協議成本,(4)重組和員工離職補償,(5)攤銷和其他併購相關成本,(6)資產減值和(資產處置盈利)/虧損,淨利,(7)訴訟(賠償)/費用,淨額和(8)債務提前償還虧損 除以(收入前所得稅調整爲上述八項).
歸屬於Cardinal Health, Inc.的非通用會計原則稀釋每股收益: Cardinal Health, Inc.歸屬的非通用會計原則淨收益除以稀釋加權平均股份。

 16
卡地納健康 | Q1 2025財年10-Q表格


非依照美國通用會計準則衡量的財務指標的解釋和調和
GAAP與非GAAP協調說明
營業收益/(損失)
營業收益增長率
稅前收益/(損失)
所得稅準備/(受益於)
淨收益/(虧損)1
淨收益1 增長率 - 不變貨幣
攤薄後每股收益1,2
攤薄後每股收益1
增長率
(以百萬美元爲單位,除每股普通股金額外)
2024年9月30日止三個月
通用會計原則(GAAP)$568 N.M.$541 $124 $416 N.M.$1.70 N.M.
重組和員工分流24 24 6 18 0.07 
攤銷及其他併購相關成本74 74 20 54 0.22 
資產處置的淨損益和資產減值
(1)(1) (1) 
訴訟(收回款項)/費用淨額 (40)(40)(12)(28)(0.11)
非通用會計原則$625 12 %$598 $138 $460 7 %$1.88 9 %
2023年9月30日止三個月
通用會計原則(GAAP)$(32)N.M.$(44)$(33)$(12)N.M.$(0.05)N.M.
重組和員工分流25 25 18 0.07 
攤銷及其他併購相關成本64 64 17 47 0.19 
資產處置的淨損益和資產減值 3
541 541 135 406 1.63 
訴訟(收入)/費用,淨額(41)(41)(12)(29)(0.12)
非通用會計原則$557 37 %$545 $114 $430 37 %$1.72 50 %
1    歸因於 Cardinal Health, Inc。
2截至2023年9月30日三個月的GAAP攤薄後每股收益和從GAAP到非GAAP每股協調項目的每股收益影響是使用24900萬普通股的加權平均值計算的,由於我們財務報表期間的GAAP淨虧損導致可能具有稀釋效果的證券被排除在分母之外。截至2023年9月30日三個月的非GAAP攤薄後每股收益是使用25000萬普通股的加權平均數計算的,其中包括可能具有稀釋效果的股份。
3    截至2023年9月30日的三個月,資產減值和資產處置淨(收益)/損失包括一筆稅前的$58500萬的商譽減值費用,與GMPD業務部門有關。在2024財年,與此費用相關的淨稅收益爲$4500萬,並已納入年度有效稅率中。因此,截至2023年9月30日的三個月的稅收益增加了約$10200萬,同時增加了2024財年餘下期間的所得稅負債。
元件總和和某些計算結果可能反映四捨五入調整。
根據商品性質和徵稅司法管轄區域的不同,我們適用不同的稅率。






卡地納健康 | Q1 2025財年10-Q表格
17



其他

有關市場風險的定量和定性披露
自2024年財政年度結束至2024年9月30日,包含在2024年10-k表格中的定量和定性市場風險披露沒有發生重大變化。
控制和程序
披露控件和程序的評估
我們評估了我們的主要執行官和信安金融官員的參與,有效性我們的披露控制與程序(在1934年證券交易法規13a-15(e)規定的「交易所法」下定義)截至2024年9月30日。根據這一評估,我們的主要執行官和信安金融官員得出結論,即截至2024年9月30日,我們的披露控制與程序有效,可以提供合理保證,以保證根據證券交易法要求披露的信息在SEC規則和表格規定的時間內記錄、處理、彙總和報告,並且這些信息被累積並適當地傳達給管理人員,以便及時做出有關所需披露的決定。
關於財務報告內控的變化
截至2024年9月30日季度結束,我們的財務報告內部控制未發生變化,對我們的財務報告內部控制造成重大影響或可能造成重大影響。

 18
卡地納健康 | Q1 2025財年10-Q表格


其他
法律訴訟
基本財務報表附註中描述的法律訴訟已納入本「法律訴訟」部分。 注7 的基本報表附註中描述的法律訴訟已納入本「法律訴訟」部分。
風險因素
您應該仔細考慮本10-Q表格中的信息和《風險因素》中討論的風險因素以及2024年10-k表格和我們自2024年6月30日以來提交給SEC的其他風險。這些風險可能會對我們的經營業績、財務狀況、流動性和現金流產生重大不利影響。我們的業務也可能受到我們目前不知情的或者我們目前認爲對我們業務不重要的風險的影響。
我們對綜合腫瘤網絡的待收購將面臨各種風險和不確定性。
根據MD&A部分討論,在2024年9月20日,我們宣佈已達成明確協議,以現金11億美元的價格收購綜合腫瘤網絡(「ION」),這是一家由醫生領導的獨立社區腫瘤網絡,價格將根據特定調整而定。此次收購將進一步發展我們的Navista腫瘤實踐聯盟,並預計將擴大我們的整體臨床和實踐管理解決方案系列,旨在支持獨立的社區腫瘤實踐。待完成的收購最終效力視多種風險和不確定性而定,例如成功按時完成收購的能力,其中包括獲得必要的監管批准和滿足其他閉包條件。
如果我們成功完成收購,我們將面臨其他風險,包括以下內容:我們可能未能實現預期的收購協同效應和其他好處;使用大部分現金可能對我們的流動性產生不利影響,限制我們在應對其他業務機會時的靈活性,並增加我們對不利經濟和行業條件的脆弱性;我們可能未能保留新收購業務的關鍵人員;未來的發展可能損害我們購買的商譽或無形資產的價值;我們可能面臨建立、適當整合或結合運營和系統方面的困難;我們可能遇到意想不到的內部控制、監管或合規問題,包括與醫療辦公室管理相關的問題;我們可能面臨與監管事項、法律訴訟和稅收法律或立場相關的其他額外風險。
未註冊的股票股權銷售和籌款用途
發行人購買股權證券
時期股票總數
股票
已購買(1)
每股平均購買價格
(2)
股票總數
已購買
作爲公開宣佈的計劃的一部分(2,3)
大致持有總股數(1)
購買的股票價值
在計劃或
計劃或
在該方案下(3)
(單位百萬)
2024年7月143 $95.46 — $3,493 
2024年8月2,736,169 109.65 2,735,978 3,193 
2024年9月723 111.72 — 3,193 
總費用2,737,035 $109.65 2,735,978 $3,193 
(1)反映了作爲我們延期薪酬計劃參與者的投資,分別於2024年7月、8月和9月通過拉比信託購買的143股、191股和723股普通股。
(2)2024年8月21日,我們參與了一個ASR計劃,以37500萬美元的總購買價購買普通股,並以每股109.65美元的參考價收到了初步交付的270萬股普通股。ASR計劃於2024年10月30日結束,每股普通股的成交量加權平均價爲110.10美元,最終交付了70萬普通股。請參見 注11 「基本財務報表附註」部分獲取更多信息。
(3)2023年6月7日,我們的董事會批准了一項新的35億美元股票回購計劃,該計劃將於2027年12月31日到期。截至2024年9月30日,我們已授權尚未使用的32億美元用於股票回購計劃。


 19
卡地納健康 | Q1 2025財年10-Q表格


其他
其他信息
規則10b5-1計劃的採納和修改
2024年9月30日結束的三個月內,沒有董事或高級職員 採納修改或終止 根據交易所法規S-k條例第408(a)節中定義的「10b5-1規則交易安排」或「非10b5-1規則交易安排」。




紅衣主教健康 | Q1 2025 財年表格 10-Q
20



基本報表
綜合損益簡明合併報表
(未經審計)
截至9月30日的三個月
(以百萬美元爲單位,除每股普通股金額外)20242023
營業收入$52,277 $54,650 
銷售產品成本50,375 52,907 
毛利率1,902 1,743 
營業費用:
分銷、銷售、一般和管理費用1,277 1,186 
重組和員工分流24 25 
攤銷及其他併購相關成本74 64 
資產處置的淨損益和資產減值(1)541 
訴訟(收入)/費用,淨額(40)(41)
營業收入
568 (32)
其他收入/費用,淨額(5)1 
利息費用,淨額32 11 
稅前收益/(損失)
541 (44)
所得稅借項(或貸項)
124 (33)
淨收益/(虧損)417 (11)
扣除:歸屬於非控股權益的淨收益
(1)(1)
淨收益(虧損)歸屬於基楚瑞健康有限公司 $416 $(12)
歸屬於Cardinal Health, Inc.的每股收益/(虧損):
基本$1.71 $(0.05)
稀釋1.70 (0.05)
普通股股份加權平均數:
基本243249
稀釋245249
每股普通股分紅派息$0.5056 $0.5006 
請參閱附註的簡明合併財務報表。

卡地納健康 | Q1 2025財年10-Q表格
21



基本報表
研發費用在2024年第二季度和前六個月保持相對穩定,主要原因是:
(未經審計)
截至9月30日的三個月
(單位百萬)20242023
淨收益/(虧損)$417 $(11)
其他綜合收益/(虧損):
外幣翻譯調整及其它5 (11)
按照稅後淨抵押工具的未實現收益/(損失)
7 (3)
其他綜合收益/(虧損)總額,淨額
12 (14)
綜合收益/(損失)總額
429 (25)
減:歸屬於非控制權益的綜合收益(1)(1)
歸屬於Cardinal Health, Inc.的綜合收益/(損失)總額
$428 $(26)
請參閱附註的簡明合併財務報表。


卡地納健康 | Q1 2025財年10-Q表格
22



基本報表
彙編的綜合資產負債表

(單位百萬)2024年9月30日2024年6月30日
資產(未經審計)
流動資產:
現金及現金等價物$2,867 $5,133 
交易應收賬款淨額11,781 12,084 
淨存貨15,619 14,957 
預付費用和其他2,591 2,663 
待售資產
47 47 
總流動資產32,905 34,884 
資產和設備,淨值2,535 2,529 
商譽及其他無形資產,淨額6,388 6,450 
其他1,231 1,258 
總資產$43,059 $45,121 
負債和股東權益虧空
流動負債:
應付賬款$30,365 $31,759 
長期負債和其他短期借款的流動部分940 434 
其他應計負債3,373 3,447 
流動負債合計34,678 35,640 
長期負債,減去流動部分4,224 4,658 
遞延所得稅及其他負債7,433 8,035 
股東虧損:
無面值優先股:
已授權—500 股份,已發行—
  
無面值普通股:
已授權—755百萬美元股份,已發行—327百萬美元股在 2024年9月30日 和2024年6月30日
2,827 2,917 
留存收益/(累積赤字)
14 (286)
庫藏普通股,成本價格: 85百萬持續經營活動中普通股股東的收益83 million shares at 2024年9月30日 and 2024年6月30日,分別
(5,963)(5,677)
累計其他綜合損失(155)(167)
總計Cardinal Health, Inc.股東赤字
(3,277)(3,213)
非控制權益1 1 
股東權益不足合計
(3,276)(3,212)
負債總額和股東權益赤字
$43,059 $45,121 
請參閱附註的簡明合併財務報表。


卡地納健康 | Q1 2025財年10-Q表格
23



基本報表
股東權益累計赤字的簡明綜合財務報表
(未經審計)
普通股份。庫藏股其他積累
綜合
損失
非控制權益
總費用
股東的
$
(單位百萬)已發行股票數量
留存盈餘/(累積虧損)
股份數量
2024年9月30日止三個月
2024年6月30日餘額327 $2,917 $(286)(83)$(5,677)$(167)$1 $(3,212)
淨收益
416 1 417 
其他綜合收益,扣除稅後
12 12 
員工股票計劃活動,扣除員工稅收後的淨股份 (15)1 17 2 
股票回購計劃活動(75)(3)(303)(378)
3,341,700(119)(119)
其他3 (1)2 
2024年9月30日的餘額327 $2,827 $14 (85)$(5,963)$(155)$1 $(3,276)
2023年9月30日止三個月
2023年6月30日的餘額327 $2,746 $(642)(76)$(4,911)$(151)$1 $(2,957)
淨收益/(虧損)(12)1 (11)
其他綜合損失,淨額(14)(14)
僱員股票計劃活動,扣除員工稅金的股份淨額 (18)1 25 7 
股份回購計劃活動(5)(505)(505)
3,341,700(125)(125)
其他(1)(1)(2)
2023年9月30日結餘327 $2,728 $(780)(80)$(5,391)$(165)$1 $(3,607)
請參閱附註的簡明合併財務報表。



卡地納健康 | Q1 2025財年10-Q表格
24



基本報表
簡明的綜合現金流量表
(未經審計)
截至9月30日的三個月
(單位百萬)20242023
經營活動現金流量:
淨收益/(虧損)$417 $(11)
調整以調和淨收益/(虧損)至由經營活動提供的現金淨額
折舊和攤銷182 172 
減值損失和投資出售(收益)/損失1  
資產處置的淨損益和資產減值(1)541 
股權酬金30 29 
壞賬準備16 9 
經營性資產和負債的變化,扣除收購和處置的影響
交易應收賬款減少
288 58 
存貨的增加
(678)(1,073)
應付賬款的增加/(減少)
(1,394)1,762 
其他應計負債和運營項目,淨額(508)(959)
經營活動提供的淨現金流量
(1,647)528 
投資活動現金流量:
淨脫售現金收入2  
固定資產的增加(90)(92)
處置固定資產所得 1 
淨投資對沖終止收益 28 
投資活動產生的淨現金流出
(88)(63)
籌集資金的現金流量:
長期負債的減少(9)(7)
股票薪酬的淨稅預扣
(28)(28)
普通股股息(128)(131)
購買公司庫存股(375)(500)
籌集資金淨額(540)(666)
現金及現金等價物的匯率變動影響9 (5)
現金及現金等價物淨減少額
(2,266)(206)
本期期初現金及等價物餘額5,133 4,076 
本期期末現金及等價物餘額$2,867 $3,870 
See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2025 Form 10-Q
25



Notes to Financial Statements
Notes to Condensed Consolidated Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "2024 Form 10-K").
Revision of Prior Period Consolidated Financial Statements
As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not
material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the "Consolidated Financial Statements" in the 2024 Form 10-K for additional information.
Updated Segment Reporting Structure
Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharma reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The GMPD reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight® Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See Note 13 for segment results under the new reporting structure.
Major Customers
On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024.
Recently Issued Financial Accounting Standards And Disclosure Rules Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from the 2024 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in the 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.

Cardinal Health | Q1 Fiscal 2025 Form 10-Q
26



Notes to Financial Statements

Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in the 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Climate-Related Disclosures
In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management, and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. We are currently evaluating the impact of adoption of these final rules on our disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the three months ended September 30, 2024.

2. Acquisitions
On September 20, 2024, we announced that we have entered into a definitive agreement to acquire Integrated Oncology Network ("ION"), a physician-led independent community oncology network, for a purchase price of $1.1 billion in cash, subject to certain adjustments. ION includes more than 50 practice sites in 10 states representing more than 100 providers. ION supports a complete continuum of care across its member sites including medical oncology, radiation oncology, urology diagnostic testing and other ancillary services. This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.
On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology.
The allocation of the purchase price for the acquisition of Specialty Networks is not yet finalized and is subject to adjustment as we complete the valuation analysis of the acquisition. The pro forma results of operations and the results of operations for Specialty Networks have not been separately disclosed because the effects were not significant compared to the consolidated financial statements.

3. Divestitures
On June 5, 2023, we signed a definitive agreement to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the three months ended September 30, 2023, which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). This gain includes our initial recognition of an equity method investment in the combined entity for $147 million, which was recorded in other assets in our condensed consolidated balance sheets.
We determined that the divestiture of the Outcomes™ business did not meet the criteria to be classified as discontinued operations. The Outcomes™ business operated within our former Pharmaceutical segment and its results before the divestiture are reflected within the Pharma segment.

4. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
Three Months Ended September 30,
(in millions)20242023
Employee-related costs$16 $7 
Facility exit and other costs8 18 
Total restructuring and employee severance$24 $25 

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional project management, and costs associated with vacant facilities.
During the three months ended September 30, 2024, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and certain initiatives to rationalize our manufacturing operations. During the three months ended September 30, 2023, restructuring and employee severance costs were primarily related to certain

Cardinal Health | Q1 Fiscal 2025 Form 10-Q
27



Notes to Financial Statements

projects resulting from reviews of our strategy, portfolio, capital-allocation framework, and operations and the implementation of certain enterprise-wide cost-savings measures.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs
Facility Exit
and Other Costs
Total
Balance at June 30, 2024$92 $5 $97 
Additions7  7 
Payments and other adjustments(5)(5)(10)
Balance at September 30, 2024$94 $ $94 

5. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the carrying amount of goodwill by segment and in total:
(in millions)Pharmaceutical and Specialty SolutionsGlobal Medical Products and DistributionOther (1)Total
Balance at June 30, 2024$3,555 $ $1,170 $4,725 
Goodwill acquired, net of purchase price adjustments    
Balance at September 30, 2024$3,555 $ $1,170 $4,725 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
During the three months ended September 30, 2023, we performed interim quantitative goodwill impairment testing for GMPD. This quantitative testing resulted in the carrying amount of GMPD exceeding the fair value, resulting in a pre-tax impairment charge of $585 million. GMPD goodwill was fully impaired during the third quarter of fiscal 2024.
Other Intangible Assets
The following tables summarize other intangible assets by class at:
September 30, 2024
(in millions)Gross
Intangible
Accumulated
Amortization
Net
Intangible
Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$12 $ $12 N/A
Total indefinite-life intangibles12  12 N/A
Definite-life intangibles:
Customer relationships3,651 2,495 1,156 11
Trademarks, trade names and patents562 415 147 7
Developed technology and other1,047 699 348 7
Total definite-life intangibles5,260 3,609 1,651 10
Total other intangible assets$5,272 $3,609 $1,663 N/A
June 30, 2024
(in millions)Gross
Intangible
Accumulated
Amortization
Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$12 $— $12 
Total indefinite-life intangibles12 — 12 
Definite-life intangibles:
Customer relationships3,628 2,431 1,197 
Trademarks, trade names and patents561 408 153 
Developed technology and other1,047 684 363 
Total definite-life intangibles5,236 3,523 1,713 
Total other intangible assets$5,248 $3,523 $1,725 
Total amortization of intangible assets was $68 million and $64 million for the three months ended September 30, 2024 and 2023, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2025 through 2029 is as follows: $200 million, $246 million, $219 million, $191 million, and $186 million.

Cardinal Health | Q1 Fiscal 2025 Form 10-Q
28



Notes to Financial Statements

6. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.2 billion and $5.1 billion at September 30, 2024 and June 30, 2024, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $30.4 billion and $31.8 billion at September 30, 2024 and June 30, 2024, respectively.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2024 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility, which expires in February 2028. We also have a $1.0 billion committed receivables sales facility through September 2025. At September 30, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.
In October 2024, we entered into a new 364-Day Revolving Credit Facility, under which we have access to $1.0 billion of committed liquidity through October 2025. We also increased our Commercial Paper program from $2.0 billion to $3.0 billion.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2024, we were in compliance with this financial covenant.

7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors that was assessed based on each
manufacturer or distributor's share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new opioid excise tax and limited the OSA to two years (2017 and 2018).
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Since fiscal 2021, we have made certain payments to New York State for our portion of the assessment in 2017 and 2018. However, we, and other distributors, challenged the OSA as unconstitutional. In May 2024, the New York Appellate Division held that the 2017 assessment was unconstitutionally retroactive, directing a refund of assessments paid for calendar year 2017, but upheld the 2018 assessment. Both parties have appealed the decision of the New York Appellate Division to the New York Court of Appeals, the state's highest court. We have not recorded a receivable for any possible recoveries related to these assessments.
Legal Proceedings
We become involved from time to time in disputes, litigation, and regulatory matters.
From time to time, we determine that products we distribute, source, manufacture, or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims, and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier, or other industry participants. Internal investigations, subpoenas, or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate

Cardinal Health | Q1 Fiscal 2025 Form 10-Q
29



Notes to Financial Statements
the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.
Opioid Lawsuits and Investigations
Cardinal Health, other pharmaceutical wholesalers, and other participants in the pharmaceutical supply chain have been named as defendants in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act, and various other statutes. Plaintiffs in these lawsuits include governmental entities, as well as private parties, such as unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals.
Additionally, we have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas, and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.
In total, as of September 30, 2024, we have $5.0 billion accrued for these matters, of which $789 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During fiscal 2024, we recognized expense of $340 million
in connection with opioid-related matters, including agreements in principle with counsel representing classes of third-party payors and acute care hospitals, and settlements with the City of Baltimore and the State of Alabama. This expense was partially offset by a benefit of $105 million related to prepayments at a prenegotiated discount of certain future payments totaling $344 million.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of the agreements described below is an admission of liability or wrongdoing. Please see below for additional description of these matters.
States & Political Subdivisions
In 2022, we along with two other national distributors (collectively, the "Distributors") entered into the National Opioid Settlement Agreement to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories that joined the National Opioid Settlement Agreement, the "Settling Governmental Entities").
During fiscal 2024, we recognized a $22 million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings/(loss) related to an agreement with the Alabama Attorney General under which we agreed to pay approximately $123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions (the "Alabama Settlement"). Including the National Opioid Settlement Agreement, the Alabama Settlement and a prior settlement with the State of West Virginia, we have now resolved the opioid-related claims of all 50 states and the District of Columbia. Additionally, in August 2024, we entered into a settlement agreement with the City of Baltimore to resolve its opioid-related claims. Under this agreement, we agreed to pay $153 million.
Under the National Opioid Settlement Agreement, through October 2024, we have paid the Settling Governmental Entities approximately $1.9 billion. We expect to pay Settling Governmental Entities additional amounts up to $4.4 billion

 30
Cardinal Health | Q1 Fiscal 2025 Form 10-Q


Notes to Financial Statements
through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors’ controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors have engaged a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions. We intend to defend ourselves vigorously against all remaining lawsuits.
Other Settlements
West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement. In July 2022, a judgment in favor of the Distributors was entered in a bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, we entered into separate agreements to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions and Native American Tribes for approximately $124 million over 11-years and $136 million over five years, respectively.
Private Plaintiffs
The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals alleging personal injury. There were approximately 367 lawsuits brought by private plaintiffs pending as of October 28, 2024. Of these, 98 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in all of these matters.
Following resolution discussions with certain private plaintiffs, during the three months ended September 30, 2024, Distributors finalized agreements with classes of third-party payors and acute care hospitals to settle their claims for $213 million. These agreements remain subject to certain contingencies, including court approval. Active litigation brought by hospital and third-party payor plaintiffs, including certain scheduled trials, has been stayed as to Distributors pending court approval of these settlements.
A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. Following cross-appeals, in September 2024, The Georgia Supreme Court affirmed the defense verdict in full.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal 2024, we received $34 million in insurance recoveries related to these matters and $9 million in the three months ended
September 30, 2024. We have not recorded a receivable for any additional recoveries related to these insurance litigation matters as of September 30, 2024. Certain recoveries from our insurers are recorded in the Pharmaceutical and Specialty Solutions segment.
Department of Justice Civil Investigative Demand
In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation.
Cordis IVC Filter Matters
We have been named as a defendant in product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.
In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, while we have also entered into agreements to settle the vast majority of IVC filter product liability claims, these settlements will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits.
We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At September 30, 2024, we had a total of $289 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets, which includes the $275 million in the qualified settlement fund.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters condensed consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided
Cardinal Health | Q1 Fiscal 2025 Form 10-Q
31



Notes to Financial Statements
anti-competitive pricing information to manufacturers, and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter, which remains pending as of September 30, 2024.
Antitrust Litigation Proceeds
We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $43 million and $41 million, which were recognized in litigation (recoveries)/charges, net, during the three months ended September 30, 2024 and 2023, respectively.
8. Income Taxes
Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings/(loss) (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Effective Tax Rate
During the three months ended September 30, 2024 and 2023, the effective tax rate was 23.0 percent and 75.1 percent, respectively. The tax rate during the three months ended September 30, 2023 reflects the impact of the tax effects of the goodwill impairment charge recognized in the same quarter.
Tax Effects of Goodwill Impairment Charge
During the three months ended September 30, 2023, we recognized a $585 million pre-tax charge for goodwill impairment related to the GMPD segment. The net tax benefit related to this charge is $45 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the three months ended September 30, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to pre-tax loss for three months ended September 30, 2023 resulted in recognizing an incremental interim tax benefit of approximately $102 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended September 30, 2023 and prepaid expenses and other assets in the condensed
consolidated balance sheets at September 30, 2023. This interim tax benefit reversed in the remainder of fiscal 2024.
Unrecognized Tax Benefits
We had $952 million and $981 million of unrecognized tax benefits at September 30, 2024 and June 30, 2024, respectively. The September 30, 2024 and June 30, 2024 balances include $871 million and $882 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At September 30, 2024 and June 30, 2024, we had $69 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) from income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits, or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $20 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.

9. Fair Value Measurements
Assets and Liabilities Measured on a Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
September 30, 2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$678 $ $ $678 
Other investments (1)105   105 
Liabilities:
Forward contracts (2) (37) (37)

 32
Cardinal Health | Q1 Fiscal 2025 Form 10-Q


Notes to Financial Statements
June 30, 2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,442 $ $ $1,442 
Other investments (1)108   108 
Liabilities:
Forward contracts (2) (87) (87)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)     The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow
management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three months ended September 30, 2024 and 2023, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the three months ended September 30, 2023 we entered into pay-floating interest rate swaps with total notional amounts of $100 million. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency, and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains recognized in other comprehensive income/(loss) were $3 million and immaterial for the three months ended September 30, 2024 and 2023, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were a $1 million loss and a $1 million gain for the three months ended September 30, 2024 and 2023, respectively. Losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be
Cardinal Health | Q1 Fiscal 2025 Form 10-Q
33



Notes to Financial Statements
reclassified into net earnings within the next 12 months are $3截至2021年3月27日,未償還本金總額爲$。
淨投資套期保值
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In September 2023, we entered into ¥18163.9120 million) cross-currency swaps maturing in September 2025 and ¥18163.91202027年6月到期的價值1億日元的跨貨幣互換交易。2024年6月,我們終止了這筆交易¥18163.9120價值1億美元的2027年6月到期的跨貨幣互換交易。
2023年9月,我們終止了這筆交易¥38163.9300價值1億美元的2023年1月簽訂的跨貨幣互換交易,並收到了淨現金結算$28淨投資頭寸套期交易終止款項,金額爲1百萬美元,在我們的簡明合併現金流量表中記錄。
指定爲淨投資套期交易的跨貨幣互換交易以現期匯率標記爲市值,截至期末,盈虧計入累積其他綜合損益的外幣折算組成部分,直至基礎淨投資的出售或實質清算。在跨貨幣互換交易指定爲淨投資套期交易的程度上不高效時,由於現貨匯率變動而導致的價值變動計入收益。
稅前收益和虧損記錄在匯率期貨的累計其他全面損失的外幣翻譯組成部分爲$22百萬美元的損失11百萬美元的收益分別爲2024年和2023年截至9月30日的三個月,利息費用淨額在簡明綜合收益(虧損)陳述中承認,從投資關聯排除的外幣翻譯的一部分的投資掩護的淨額投資翻譯排除的部分爲$21百萬美元和3百萬美元分別爲2024年和2023年截至9月30日的三個月內。
經濟(非指定)套期保值
我們進行外匯合約以管理與銷售交易、公司間融資交易和其他需要重新計價的資產負債表項目相關的外匯風險。因此,這些衍生工具在每個期間末調整爲當前市場價值,通過收入額體現。這些工具上記錄的盈利或損失基本上被外幣標價資產或負債的重新計量調整所抵消。外匯衍生工具的結算和外幣標價資產或負債的重新計量調整都記錄在其他收入/支出中。我們在2024年和2023年截至9月30日的三個月內分別記錄了一筆$1百萬美元的虧損和一筆無形利潤。主要通過外匯合約管理的貨幣是
歐元、人民幣、加幣、印度盧比和巴西雷亞爾。
金融工具的公允價值
截至2024年9月30日和2024年6月30日,現金及等價物、應收賬款、應付賬款和其他應計負債的賬面價值由於短期到期日接近其公允價值。
以下表格總結了我們的長期債務和其他短期借款的預計公允價值與對應賬面價值相比:
(單位百萬)2024年9月30日2024年6月30日
估計公允價值$5,072 $4,891 
賬面餘額5,164 5,092 
我們的長期債務和其他短期借款的公允價值是根據相同或類似問題的報價市場價格或來源於可獲得市場信息的其他輸入來估算的,這代表了二級測量。
11. 股東赤字
在截至2024年9月30日的三個月內,我們參與了一項加速股份回購("ASR")計劃,以總購買價格爲$375 百萬。我們使用參考價格爲$ 2.7 百萬普通股進行了初始交割。該計劃於2024年10月30日結束,每普通股成交均價爲$109.65,最終交割了110.10 0.7 百萬普通股。
截至2023年9月30日的三個月內,我們參與了一個ASR計劃,以總購買價值$500 百萬普通股。我們以$ 4.4作爲參考價格,收到了初始交付的90.57百萬普通股。該計劃於2023年10月31日結束,每普通股的成交量加權平均價格爲$88.22 ,最終交付了 1.3一百萬普通股份。
我們用可用現金進行回購。回購的普通股被持有在公司財務用途的庫存中。

 34
卡地納健康 | Q1 2025財年10-Q表格


財務報表說明

累計其他綜合損失
以下表格總結了各組成部分和總計累積其他綜合損失餘額的變動情況:
(單位百萬)外幣
貨幣
累計折算差額(2)
調整
未實現的
收益/(損失)
Derivatives,
稅後淨額
其他積累
綜合
損失
2024年6月30日餘額$(138)$(29)$(167)
其他綜合收益,重新分類前
5 6 11 
重新分類的金額 1 1 
卡地納健康公司歸屬的其他綜合收益合計,減稅益$5百萬
5 7 12 
2024年9月30日的餘額$(133)$(22)$(155)
(單位百萬)外幣
貨幣
累計折算差額(2)
調整
未實現的
收益/(損失)
Derivatives,
稅後淨額
其他積累
綜合
損失
2023年6月30日的餘額$(137)$(14)$(151)
其他全面損失(再分類前)(11)(1)(12)
重新分類的金額 (2)(2)
卡地納健康公司的其他綜合損失總額,扣除稅後支出$3百萬
(11)(3)(14)
2023年9月30日結餘$(148)$(17)$(165)

12. 每股收益/(損失) 歸屬於卡地納健康公司
下表調解了用於計算歸屬於卡地納健康公司的基本和攤薄後每股收益("EPS")的普通股數量:
截至9月30日的三個月
(單位百萬)20242023
基本攤薄後每股收益加權平均普通股243 249 
攤薄效應:
員工股票期權、限制性股份單位和業績股份單位2  
攤薄後每股收益加權平均普通股245 249 
在2024年9月30日結束的三個月中,未包括在攤薄後每股收益計算中的潛在攤薄員工股票期權、限制性股份單位和業績股份單位對於財務影響不大 2 在2023年9月30日結束的三個月中爲百萬美元 1 million of which were anti-dilutive as a result of the net loss during the period.

13. Segment Information
Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under 兩個 reportable segments: Pharma segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.
Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
我們的GMPD部門製造、來源和分銷卡地納健康品牌的醫療、外科和實驗室產品,在美國、加拿大、歐洲、亞洲和其他市場銷售。除了分銷卡地納健康品牌產品外,該部門還向美國和加拿大的醫院、門診手術中心、臨床實驗室和其他醫療保健提供者分銷一系列國家品牌產品的醫療、外科和實驗室產品。
除了討論過的主要現場之外,沒有現場在總準備金中佔據重要地位。未來還有多個事件尚未發生,包括進一步的治療選擇和設計,治療實施和執行,以及獲得適用的政府機構批准,所有這些都有可能增加這些未來事件的不確定性。隨着這些事件的發生和環境治理成本估算的變化,現有準備金將進行調整。 包括在其他板塊中的不需要報告的營業部門有核醫學和精準健康解決方案、家庭解決方案和OptiFreight。® 物流。這些營業部門分別經營核藥房和放射性藥物製造設施,在美國向患者家中分銷醫療產品,並向客戶提供供應鏈服務和解決方案。
卡地納健康 | Q1 2025財年10-Q表格
35



財務報表說明


營業收入
下表顯示了兩個報告領域的營業收入以及其他營運領域(包括其他和公司)內的細分營業收入:
截至9月30日的三個月
(單位百萬)20242023
醫療藥品和特色解決方案$47,990 $50,588 
全球貨幣醫療產品和分銷3,123 3,032 
核能和精準醫療解決方案373 324 
家庭解決方案739 667 
OptiFreight® 物流
74 60 
其他1,186 1,051 
該板塊的總營業收入
52,299 54,671 
企業(1)(22)(21)
總收入$52,277 $54,650 
(1)企業營業收入包括取消分部間營業收入和未分配至各分部的其他收入。
以下表格顯示按地理區域劃分的營業收入:
截至9月30日的三個月
(單位百萬)20242023
美國$51,891 $54,270 
國際408 401 
該板塊的總營業收入
52,299 54,671 
企業(1)(22)(21)
總收入$52,277 $54,650 
(1)企業營業收入包括消除分部之間的內部收入和未分配給各個分部的其他收入。
分段利潤
我們根據分部利潤等指標評估分部業績。分部利潤是分部營業收入減去分部銷售產品成本、減去分部分銷、銷售、總務和管理費用("SG&A")等。分部SG&A費用包括基於股份報酬支出以及分配的企業科技和共享功能支出,包括企業管理、企業金融、金融和客戶服務共享服務、人力資源、信息技術以及法律和合規,包括特定訴訟防禦成本。企業費用根據員工人數、提供的福利水平以及其他分攤方法分配給各個分部。歸屬於非控股權益的業績記錄在分部利潤內。
我們不將以下項目分配給我們的各個分部:
先進先出,或("LIFO"),存貨費用/(貸項);
與先前財政年度相關的州防止鴉片產品評估;
股東合作協議成本;
重組和員工離職費用;
攤銷和其他與收購相關的成本;
資產減值及資產處置損益,淨額;在2023年9月30日結束的三個月中,我們承認了一項稅前商譽減值費用爲$585百萬;
訴訟(收入)/費用,淨額;
其他(收入)/費用,淨額;
利息費用,淨額;
債務提前清償損失;
所得稅負債/(收益)
此外,某些投資支出和企業範圍內的激勵報酬和其他支出的某些部分未分配給各個部門。投資支出通常包括需要額外營業費用形式的增量投資的某些項目的首年支出。由於這些項目的批准取決於高管層,我們將這些費用保留在公司層面。公司層面的投資支出分別爲$12萬美元和6萬美元,截至2024年和2023年9月30日的三個月分別爲。
以下表格展示了兩個可報告部門以及其他運營部門(包括其他)和公司層面的部門利潤:
截至9月30日的三個月
(單位百萬)20242023
醫療藥品和特色解決方案$530 $456 
全球貨幣醫療產品和分銷8 12 
其他(1)104 96 
總業務利潤642 564 
公司(74)(596)
總營業收益/(損失)
$568 $(32)
(1) 包括其餘營運部門,核能和精密健康解決方案,家庭解決方案,以及OptiFreight® 物流。

業務資產
以下表格顯示了兩個報告部門和其他運營部門(包括其他和企業部門)的總資產:
(單位百萬)2024年9月30日2024年6月30日
醫療藥品和特色解決方案$29,215 $29,149 
全球貨幣醫療產品和分銷7,148 7,047 
其他2,611 2,606 
公司
4,085 6,319 
總資產$43,059 $45,121 


 36
Cardinal Health | Q1 Fiscal 2025 Form 10-Q


Notes to Financial Statements

14. 分享基礎的薪酬
我們爲部分高管、董事和員工設立股票激勵計劃(總稱「計劃」)。
下表提供按獎勵類型劃分的總股份酬勞支出:
截至9月30日的三個月
(單位百萬)20242023
限制性股份單位費用$19 $21 
業績股單位費用11 8 
總的股份報酬
$30 $29 
與基於股份補償的總稅收優惠有關的金額爲$4截至2024年9月30日和2023年9月30日的三個月分別爲百萬美元。
受限股份單位
根據計劃授予的限制性股份單位通常在相等的年度分期內授予。 三年限制性股份單位積累現金股息等同價值,可在授予獎勵時支付。
以下表總結了與計劃下限制性股份單位相關的所有交易。
(單位:百萬美元,每股金額爲美元)受限股份單位平均
授予日期公允價值
每股價值
在2024年6月30日之前未授予的1.7 $70.98 
已行權0.7 107.88 
34,105(0.8)72.19 
被取消和沒收  
2024年9月30日的未投資股1.6 $90.60 
2024年9月30日,尚未確認的非載有限制性股票單位的總稅前補償成本,扣除預計的棄權費用,爲$110 百萬美元,預計在加權平均期限內確認。 發生.
績效股票單位
績效股份單位在一個 年績效期間內,根據特定績效目標的實現程度而獲得。根據目標的達成程度以及我們的總股東回報率與標普500醫療保健指數的相對情況,獲授股份的區間可能爲 240 目標獎勵金額的百分比。績效股份單位會積累現金股息等效值,該等值將在授予股票後支付。
以下表總結了與計劃下績效股份單位相關的所有交易(基於目標獎勵金額):
(單位:百萬美元,每股金額爲美元)表現
股份單位
平均
授予日期公允價值
每股價值
在2024年6月30日之前未授予的1.3 $97.03 
已行權0.4 113.88 
34,105(0.3)108.78 
被取消和沒收  
2024年9月30日的未投資股1.4 $98.81 
截至2024年9月30日,尚未確認的非實現績效股份單位相關的總稅前補償成本淨額,扣除估計的棄權金額爲$63 百萬美元,預計在加權平均期限內確認。 發生 如果實現了績效目標。

卡地納健康 | Q1 2025財年10-Q表格
37



展示資料
展示資料
展示文件
數量
附件描述
3.1
3.2
10.1
10.2
31.1
31.2
32.1
99.1
101.SCH行內XBRL分類擴展模式文檔
101.CALInline XBRL稅務分類擴展計算鏈接庫文檔
101.DEFInline XBRL分類定義鏈接庫文件
101.LAB行內XBRL分類擴展標籤鏈接庫文檔
101.PRE行內XBRL分類擴展演示鏈接庫文檔
104封面互動數據文件-以內聯XBRL格式(作爲附件101包含)
根據S-K規定第601(b)(10)(iv)條款,本展示的某些條款已被省略。

卡地納健康官網
卡地納健康將其網站用作材料公司信息發佈的渠道。重要信息,包括新聞發佈、財務信息、收益和分析師展示,以及關於即將舉行的展示和活動的信息經常發帖並可在ir.cardinalhealth.com上進行查看。此外,該網站允許投資者和其他感興趣的人自動註冊,以在我們在其網站上發帖新聞發佈、SEC文件以及特定其他信息時接收電子郵件提醒。


 38
卡地納健康 | Q1 2025財年10-Q表格


10-Q表格交叉索引


10-Q表格交叉索引
物品編號頁面
第一部分財務信息
第 1 項
第 2 項
第 3 項
第 4 項
第二部分。其他信息
第 1 項
第 1A 項
第 2 項
第 3 項優先證券違約 不適用
第 4 項礦山安全披露 不適用
第 5 項
第 6 項
無數據不適用



Cardinal Health | Q1 Fiscal 2025 Form 10-Q
39



Additional Information
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cardinal Health, Inc.
Date:November 1, 2024/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


 40
Cardinal Health | Q1 Fiscal 2025 Form 10-Q